Ingevity (NYSE:NGVT) Releases FY 2026 Earnings Guidance

Ingevity (NYSE:NGVT) updated its FY 2026 earnings guidance on Wednesday. The company provided EPS guidance of 4.800-5.20 for the period, compared to the consensus EPS estimate of 4.760. The company issued revenue guidance of $1.1 billion-$1.2 billion, compared to the consensus revenue estimate of $1.2 billion.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. BMO Capital Markets upped their price objective on shares of Ingevity from $64.00 to $70.00 and gave the company an “outperform” rating in a report on Wednesday, December 10th. Wells Fargo & Company boosted their price target on shares of Ingevity from $60.00 to $65.00 and gave the company an “equal weight” rating in a research report on Wednesday, January 28th. Jefferies Financial Group restated a “buy” rating and set a $82.00 price target on shares of Ingevity in a research note on Thursday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Ingevity in a research note on Thursday, January 22nd. Finally, Wall Street Zen cut shares of Ingevity from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 21st. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $72.33.

Ingevity Price Performance

Ingevity stock traded down $0.14 during mid-day trading on Friday, hitting $70.38. 132,269 shares of the company traded hands, compared to its average volume of 308,487. The stock has a fifty day moving average price of $66.96 and a 200-day moving average price of $58.99. The stock has a market cap of $2.53 billion, a price-to-earnings ratio of -15.14 and a beta of 1.34. Ingevity has a one year low of $28.49 and a one year high of $77.46. The company has a debt-to-equity ratio of 8.39, a quick ratio of 0.80 and a current ratio of 1.27.

Ingevity (NYSE:NGVT) last announced its quarterly earnings data on Wednesday, February 25th. The company reported $0.58 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.74 by ($0.16). The business had revenue of $255.10 million during the quarter, compared to analysts’ expectations of $257.27 million. Ingevity had a negative net margin of 13.51% and a positive return on equity of 100.39%. Ingevity’s revenue for the quarter was down 3.2% on a year-over-year basis. During the same period last year, the company posted $0.95 EPS. Ingevity has set its FY 2026 guidance at 4.800-5.20 EPS. On average, equities analysts predict that Ingevity will post 4.45 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Ingevity by 311.8% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 600,380 shares of the company’s stock valued at $23,769,000 after acquiring an additional 454,579 shares in the last quarter. Simcoe Capital Management LLC lifted its holdings in shares of Ingevity by 188.8% during the second quarter. Simcoe Capital Management LLC now owns 624,935 shares of the company’s stock valued at $26,928,000 after purchasing an additional 408,508 shares in the last quarter. Boston Partners boosted its position in shares of Ingevity by 141.6% during the fourth quarter. Boston Partners now owns 620,360 shares of the company’s stock valued at $36,719,000 after buying an additional 363,584 shares during the last quarter. Goldman Sachs Group Inc. increased its holdings in Ingevity by 137.7% in the 4th quarter. Goldman Sachs Group Inc. now owns 424,038 shares of the company’s stock worth $25,095,000 after buying an additional 245,620 shares in the last quarter. Finally, Marshall Wace LLP boosted its holdings in shares of Ingevity by 217.4% during the 3rd quarter. Marshall Wace LLP now owns 228,201 shares of the company’s stock valued at $12,594,000 after acquiring an additional 156,301 shares during the last quarter. Hedge funds and other institutional investors own 91.59% of the company’s stock.

About Ingevity

Ingevity Corporation, traded as NGVT, is a specialty chemicals and performance materials company headquartered in North Charleston, South Carolina. The company operates two primary business units: Performance Chemicals and Performance Materials. The Performance Chemicals segment produces and markets specialty chemicals derived largely from wood and other natural feedstocks, including rosin acids, tall oil fatty acids and esters, as well as specialty petroleum resins. These products serve a broad range of industries, including paper, adhesives, coatings, oilfield drilling and consumer goods.

The Performance Materials segment develops and manufactures activated carbon products and composites for applications such as automotive emissions control, industrial air and water purification, and spill containment.